Lesson 5

Published laser studies establish tPBM as a biologically active, non-invasive neuromodulatory therapy with a favorable safety profile. Mechanistic data from animal models and neuroimaging biomarker changes in human trials confirm that transcranial laser light engages neural substrates involved in TBI, stroke, and neurodegeneration. While early-phase trials show promising efficacy in depression and AD, larger, multicenter randomized trials with standardized laser parameters—wavelength, irradiance, pulsing, and anatomical targeting—are needed to define optimal protocols and secure regulatory indications. For treatment-resistant or chronic neurological conditions, multi-watt NIR laser systems currently offer the most compelling evidence for durable clinical benefit.